Severe Hypertriglyceridemia (SHTG) Epidemiology

DelveInsight’s, “Severe Hypertriglyceridemia Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Severe Hypertriglyceridemia Understanding

Severe Hypertriglyceridemia Overview

Severe hypertriglyceridemia is a metabolic disorder characterized by markedly elevated plasma triglyceride (TG) levels, typically exceeding 500 mg/dL and often surpassing 1000 mg/dL in advanced cases. The condition results from abnormal metabolism and clearance of triglyceride-rich lipoproteins, including chylomicrons and very low-density lipoproteins (VLDL). Severe hypertriglyceridemia is clinically important because it is strongly associated with an increased risk of acute pancreatitis and contributes to long-term cardiovascular complications. 

Common symptoms of severe hypertriglyceridemia include recurrent abdominal pain, nausea, vomiting, fatigue, and symptoms associated with acute pancreatitis. Patients may also develop eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and milky or lipemic plasma due to excessive circulating chylomicrons. Acute pancreatitis is one of the most serious complications and may present with severe epigastric pain radiating to the back, fever, and systemic inflammatory responses. Chronic hypertriglyceridemia is additionally associated with increased cardiovascular risk, insulin resistance, and fatty liver disease, contributing to substantial long-term morbidity. 

The pathophysiology of severe hypertriglyceridemia involves an imbalance between the production and clearance of triglyceride-rich lipoproteins. Under normal physiological conditions, triglycerides are transported through chylomicrons and VLDL particles and metabolized primarily by lipoprotein lipase (LPL). In severe hypertriglyceridemia, impaired LPL activity, excessive hepatic VLDL synthesis, or defective clearance of triglyceride-rich particles leads to their accumulation in plasma. Genetic mutations affecting LPL, apolipoprotein C-II, apolipoprotein A-V, GPIHBP1, and related metabolic pathways can severely disrupt triglyceride metabolism and result in familial chylomicronemia syndrome. Secondary metabolic conditions such as insulin resistance and diabetes further increase hepatic triglyceride production while simultaneously reducing peripheral triglyceride clearance. Excess chylomicron accumulation increases plasma viscosity and may promote pancreatic ischemia, free fatty acid toxicity, and inflammatory injury, ultimately contributing to acute pancreatitis. 

The etiology of severe hypertriglyceridemia is multifactorial and includes both primary genetic disorders and secondary acquired causes. Primary forms are commonly associated with inherited abnormalities in genes regulating triglyceride metabolism, particularly those involving LPL and associated cofactors. Familial chylomicronemia syndrome represents a rare monogenic disorder characterized by profound impairment in chylomicron clearance and extremely elevated triglyceride levels. More commonly, patients exhibit polygenic susceptibility combined with secondary metabolic triggers. 

The diagnosis of hypertriglyceridemia is established via a fasting lipid panel, with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines classifying the condition into mild (triglycerides 150–199 mg/dL), high (200–499 mg/dL), and very high (>500 mg/dL). When triglyceride levels exceed 400 mg/dL, the Friedewald equation for calculating LDL-C becomes unreliable and tends to underestimate the true value; therefore, non-HDL-C (total cholesterol minus HDL cholesterol) or direct LDL-C measurement is recommended. 

Management of severe hypertriglyceridemia focuses on reducing triglyceride levels, preventing acute pancreatitis, and minimizing long-term cardiovascular risk. Lifestyle modification remains the foundation of therapy and includes strict dietary fat restriction, weight reduction, regular physical activity, alcohol avoidance, and optimization of glycemic control in diabetic patients. Pharmacological treatment commonly involves fibrates, omega-3 fatty acids, statins, and niacin depending on triglyceride severity and cardiovascular risk profile. In familial chylomicronemia syndrome, extremely low-fat diets are often necessary because conventional lipid-lowering therapies may have limited efficacy. Emerging therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 (ANGPTL3) are showing promise in improving triglyceride clearance and reducing pancreatitis risk.

"Severe Hypertriglyceridemia Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Severe Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Severe Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Severe Hypertriglyceridemia Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Severe Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Severe Hypertriglyceridemia.

Severe Hypertriglyceridemia Emerging Drugs Analysis

This segment of the Severe Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Severe Hypertriglyceridemia Emerging Drugs

Plozasiran: Arrowhead Pharmaceuticals, Inc.

Plozasiran (formerly ARO-APOC3) is designed to reduce the production of the protein Apolipoprotein-CIII (ApoC3) through the natural RNA interference (RNAi) mechanism. ApoC3 is a protein that is produced in liver cells and inhibits the formation and clearance of various lipids and lipoproteins, including triglycerides. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Severe Hypertriglyceridemia.

Solbinsiran: Eli Lilly and Company

LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver. The reduction of ANGPTL3 protein will reduce certain classes of circulating lipids. It is being studied for the treatment of severe hypertriglyceridemia (sHTG). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Severe Hypertriglyceridemia.

CTX-310: CRISPR Therapeutics

CTX310 is an investigational, lipid nanoparticle (LNP) delivered CRISPR/Cas9 therapy designed to precisely edit the ANGPTL3 gene in hepatocytes following a single-course IV administration. ANGPTL3 encodes a key protein that regulates TG and LDL levels, both well-established risk factors for atherosclerotic cardiovascular disease (ASCVD). Individuals with naturally occurring loss-of-function mutations in ANGPLT3 have lower TG, lower LDL and a reduced lifetime risk of cardiovascular disease compared to those without such mutations. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Severe Hypertriglyceridemia.

Further product details are provided in the report……..

Severe Hypertriglyceridemia Drug Therapeutic Assessment

This segment of the report provides insights about the different Severe Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Severe Hypertriglyceridemia Players in Severe Hypertriglyceridemia

There are approx. 8+ key companies which are developing the therapies for Severe Hypertriglyceridemia. The companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. Phase III include, Arrowhead Pharmaceuticals, Inc.

Severe Hypertriglyceridemia Clinical Trial Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Severe Hypertriglyceridemia Drug Route of Administration

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Severe Hypertriglyceridemia Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Severe Hypertriglyceridemia Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Severe Hypertriglyceridemia Clinical Trial Activities 

The Severe Hypertriglyceridemia Pipeline report provides insights into different Severe Hypertriglyceridemia Clinical Trial within Phase II, I, preclinical and discovery stage. It also analyses Severe Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Severe Hypertriglyceridemia Pipeline Development Activities

The Severe Hypertriglyceridemia Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypertriglyceridemia drugs.

Severe Hypertriglyceridemia Pipeline Report Insights

• Severe Hypertriglyceridemia Pipeline Analysis
• Severe Hypertriglyceridemia Therapeutic Assessment
• Severe Hypertriglyceridemia Unmet Needs
• Impact of Severe Hypertriglyceridemia Drugs

Severe Hypertriglyceridemia Pipeline Report Assessment

• Severe Hypertriglyceridemia Pipeline Product Profiles
• Severe Hypertriglyceridemia Therapeutic Assessment
• Severe Hypertriglyceridemia Pipeline Assessment
• Severe Hypertriglyceridemia Inactive drugs assessment
• Severe Hypertriglyceridemia Market Unmet Needs

Key Questions Answered In the Severe Hypertriglyceridemia Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Severe Hypertriglyceridemia drugs?
• How many Severe Hypertriglyceridemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Hypertriglyceridemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Hypertriglyceridemia therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Severe Hypertriglyceridemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Severe Hypertriglyceridemia Key Players

• Arrowhead Pharmaceuticals, Inc.
• Eli Lilly and Company
• CRISPR Therapeutics
• 89bio, Inc.
• Ionis Pharmaceuticals, Inc.

Severe Hypertriglyceridemia Key Products

• Plozasiran
• Solbinsiran
• CTX-310
• Pegozafermin
• ION-775